Head-To-Head Comparison: Altimmune (NASDAQ:ALT) & Insmed (NASDAQ:INSM)

Altimmune (NASDAQ:ALT) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Volatility & Risk

Altimmune has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Valuation & Earnings

This table compares Altimmune and Insmed”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40,000.00	10,844.49	-$88.09 million	($0.78)	-2.86
Insmed	$606.42 million	34.32	-$1.28 billion	($4.11)	-23.18

Altimmune has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

78.0% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Altimmune and Insmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Altimmune	N/A	-31.41%	-26.96%
Insmed	-76.94%	-123.94%	-44.30%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Altimmune and Insmed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1	1	8	0	2.70
Insmed	1	1	22	1	2.92

Altimmune currently has a consensus target price of $14.33, indicating a potential upside of 542.75%. Insmed has a consensus target price of $200.30, indicating a potential upside of 110.21%. Given Altimmune’s higher probable upside, equities research analysts plainly believe Altimmune is more favorable than Insmed.

Summary

Altimmune beats Insmed on 9 of the 15 factors compared between the two stocks.

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.